Center-Authored Papers

Filters: Author is Wilbur, D Scott  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
No Keywords
Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur SD, Lin Y, Stone D, Axworthy D et al..  2007.  Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.. Blood. 109(11):4980-7. Abstract
Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur SD, Gopal AK et al..  2007.  Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.. Cancer research. 67(12):5921-8. Abstract
2008
Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
Pagel JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur SD, Gopal AK, Green DJ et al..  2008.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.. Blood. 111(4):2261-8. Abstract
2009
Nakamae H, Wilbur SD, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R et al..  2009.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.. Cancer research. 69(6):2408-15. Abstract
Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur SD, Fisher DR, Rajendran JG et al..  2009.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.. Blood. 114(6):1226-35. Abstract
Pagel JM, Orgun N, Hamlin DK, Wilbur SD, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.  2009.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.. Blood. 113(20):4903-13. Abstract
Wilbur SD, Thakar MS, Hamlin DK, Santos EB, Chyan M-K, Nakamae H, Pagel JM, Press OW, Sandmaier BM.  2009.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.. Bioconjugate chemistry. 20(10):1983-91. Abstract
2010
Nakamae H, Kerbauy FR, Wilbur SD, Bethge W, Hamlin DK, Santos EB, Storb R, Sandmaier BM.  2010.  Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.. Transplantation. 89(11):1336-40. Abstract
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
Wilbur SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
2011
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
2012
Wilbur SD, Chyan M-K, Nakamae H, Chen Y, Hamlin DK, Santos EB, Kornblit BT, Sandmaier BM.  2012.  Reagents for astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-de. Bioconjugate chemistry. 23(3):409-20. Abstract
Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur SD, Storer BE, Storb R, Sandmaier BM.  2012.  Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.. Blood. 119(5):1130-1138. Abstract
2013
Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur SD, Fisher DR, Frayo SL, Hylarides MD, Green DJ et al..  2013.  Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.. Blood. 121(18):3759-67. Abstract
Acetylgalactosamine
Wilbur SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
Alpha Particles
Nakamae H, Wilbur SD, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R et al..  2009.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.. Cancer research. 69(6):2408-15. Abstract
Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur SD, Storer BE, Storb R, Sandmaier BM.  2012.  Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.. Blood. 119(5):1130-1138. Abstract
Animals
Pagel JM, Orgun N, Hamlin DK, Wilbur SD, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.  2009.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.. Blood. 113(20):4903-13. Abstract
Wilbur SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
Subbiah K, Hamlin DK, Pagel JM, Wilbur SD, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW.  2003.  Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 44(3):437-45. Abstract
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
Wilbur SD, Thakar MS, Hamlin DK, Santos EB, Chyan M-K, Nakamae H, Pagel JM, Press OW, Sandmaier BM.  2009.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.. Bioconjugate chemistry. 20(10):1983-91. Abstract
Nakamae H, Kerbauy FR, Wilbur SD, Bethge W, Hamlin DK, Santos EB, Storb R, Sandmaier BM.  2010.  Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.. Transplantation. 89(11):1336-40. Abstract